Evidence supporting the use of: NADH
For the health condition: Parkinson's Disease

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

NADH (nicotinamide adenine dinucleotide + hydrogen) has been investigated as a potential treatment for Parkinson’s Disease (PD) due to its role in cellular energy metabolism and mitochondrial function. The rationale is based on evidence that mitochondrial dysfunction and oxidative stress contribute to the pathogenesis of PD. Several small clinical studies, primarily from the 1990s and early 2000s, have explored the efficacy of NADH supplementation in improving symptoms of PD. Some open-label and uncontrolled studies reported mild to moderate symptomatic improvements, particularly in motor function, when patients received intravenous or oral NADH. However, these studies were limited by small sample sizes, lack of blinding, and short duration. A few randomized controlled trials exist, but the results have been inconsistent, and the overall quality of evidence is low. Major neurological and movement disorder societies do not currently endorse NADH as a standard therapy for PD, citing insufficient robust clinical evidence. In summary, while there is a scientific rationale and some preliminary clinical research supporting the use of NADH in Parkinson's Disease, the evidence is limited and of low quality, resulting in a low confidence rating for its effectiveness.

More about NADH
More about Parkinson's Disease

Products containing NADH

We currently have no products on Vitabase that contain this ingredient.